Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LY M003

Next Previous
Drug Profile

LY M003

Alternative Names: LY-M003

Latest Information Update: 18 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lingyi Biotech
  • Class Gene therapies
  • Mechanism of Action Copper-transporting ATPase replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatolenticular degeneration

Most Recent Events

  • 18 Jun 2026 Lingyi Biotech plans a phase I/II trial for Hepatolenticular degeneration (Treatment experienced) (IV) in June 2026 (NCT07641140)
  • 11 Nov 2025 Efficacy and adverse events data from phase I trial for hepatolenticular degeneration presentation at the Liver Meeting 2025: 76th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2025)
  • 24 Sep 2024 Phase-I for Hepatolenticular degeneration (Treatment experienced, In children, In adolescent, In adults) in China (IV) (NCT06650319)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top